Natural killer cell-specific chimeric antigen receptor and use thereof
AssigneesThe Asan Foundation, University of Ulsan Foundation for Industry Cooperation
InventorsHun Sik KIM, Hyo Jin PARK, Eunbi YI
Life of this patent
Estimating the term…
Abstract
A chimeric antigen receptor (CAR), including an antigen-binding domain, a CD8 or CD28 hinge domain, a DAP10 cytoplasmic domain, a 2B4 cytoplasmic domain, and a CD3z cytoplasmic domain, where the CAR is expressed in natural killer (NK) cells. A method for treating cancer, including administering a therapeutically effective amount of a composition containing a NK cell that expresses the CAR, or a therapeutically effective amount of a cellular therapeutic agent containing a NK cell that expresses the CAR, to a subject in need thereof.
Claims20
A chimeric antigen receptor (CAR), comprising:
- (i) an antigen-binding domain;
- (ii) a CD8 or CD28 hinge domain;
- (iii) a DAP10 cytoplasmic domain;
- (iv) a 2B4 cytoplasmic domain;
- and
- (v) a CD3z cytoplasmic domain,
- wherein the CAR is expressed in natural killer (NK) cells.
15-17. (canceled)
20-25. (canceled)
Dependencies are inferred from the claim text.